• 1
    Pouchelon JL, Jamet N, Gouni V, et al. Effect of benazepril on survival and cardiac events in dogs with asymptomatic mitral valve disease: A retrospective study of 141 cases. J Vet Intern Med 2008;22:905914.
  • 2
    Campbell FE, Thomas WP, Miller SJ, et al. Immediate and late outcomes of transarterial coil occlusion of patent ductus arteriosus in dogs. J Vet Intern Med 2006;20:8396.
  • 3
    Wess G, Thomas WP, Berger DM, et al. Applications, complications, and outcomes of transvenous pacemaker implantation in 105 dogs (1997–2002). J Vet Intern Med 2006;20:877884.
  • 4
    Sykes JE, Kittleson MD, Chomel BB, et al. Clinicopathologic findings and outcome in dogs with infective endocarditis: 71 cases (1992–2005). J Am Vet Med Assoc 2006;228:17351747.
  • 5
    Kvart C, Häggström J, Pedersen HD, et al. Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation. J Vet Intern Med 2002;16:8088.
  • 6
    Atkins CE, Keene BW, Brown WA, et al. Results of the veterinary enalapril trial to prove reduction in onset of heart failure in dogs chronically treated with enalapril alone for compensated, naturally occurring mitral valve insufficiency. J Am Vet Med Assoc 2007;231:10611069.
  • 7
    Häggström J, Boswood A, O'Grady M, et al. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring Myxomatous Mitral valve disease: The QUEST study. J Vet Intern Med 2008;22:11241135.
  • 8
    Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med 2005;352:875883.
  • 9
    Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task force on sudden cardiac death of the European society of cardiology. Eur Heart J 2001;22:13741450.
  • 10
    Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. European society of cardiology. Update of the guidelines on sudden cardiac death of the European society of cardiology. Eur Heart J 2003;24:1315.
  • 11
    The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Eng J Med 1992;327:685691.
  • 12
    Cohn JN, Tognoni G. Valsartan heart failure trial investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:16671675.
  • 13
    Konstam MA, Poole-Wilson PA, Dickstein K, et al. Design of the heart failure endpoint evaluation of AII-antagonist Losartan (HEAAL) study in patients intolerant to ACE-inhibitor. Eur J Heart Fail 2008;10:899906.
  • 14
    Wong CK, Tang EW, Herbison P. The use of different evidence-based medications and 5-year survival after an acute coronary syndrome: An observational study. Int J Cardiol 2008, January 10 [Epub ahead of print].
  • 15
    Saha SA, Molnar J, Arora RR. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: A pooled meta-analysis of randomized placebo-controlled clinical trials. Diabetes Obes Metab 2008;10:4152.
  • 16
    López-Sendón J, Swedberg K, McMurray J, et al. Task Force on ACE-inhibitors of the European society of cardiology. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The task force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 2004;25:14541470.
  • 17
    Grauer GF, Greco DS, Getzy DM, et al. Effects of enalapril versus placebo as a treatment for canine idiopathic glomerulonephritis. J Vet Intern Med 2000;14:526533.
  • 18
    Grodecki KM, Gains MJ, Baumal R, et al. Treatment of X-linked hereditary nephritis in Samoyed dogs with angiotensin converting enzyme (ACE) inhibitor. J Comp Pathol 1997;117:209225.
  • 19
    Serres FJ, Chetboul V, Tissier R, et al. Doppler echocardiography-derived evidence of pulmonary arterial hypertension in dogs with degenerative mitral valve disease: 86 cases (2001–2005). J Am Vet Med Assoc 2006;229:17721778.
  • 20
    Gouni V, Serres FJ, Pouchelon JL, et al. Quantification of mitral valve regurgitation in dogs with degenerative mitral valve disease by use of the proximal isovelocity surface area method. J Am Vet Med Assoc 2007;231:399406.
  • 21
    Zoghbi WA, Enriquez-Sarano M, Foster E, et al. American society of echocardiography. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003;16:777802.